ZA201606519B - S1p modulator immediate release dosage regimen - Google Patents

S1p modulator immediate release dosage regimen

Info

Publication number
ZA201606519B
ZA201606519B ZA2016/06519A ZA201606519A ZA201606519B ZA 201606519 B ZA201606519 B ZA 201606519B ZA 2016/06519 A ZA2016/06519 A ZA 2016/06519A ZA 201606519 A ZA201606519 A ZA 201606519A ZA 201606519 B ZA201606519 B ZA 201606519B
Authority
ZA
South Africa
Prior art keywords
modulator
immediate release
dosage regimen
release dosage
regimen
Prior art date
Application number
ZA2016/06519A
Other languages
English (en)
Inventor
Frank Dahlke
Emeric Reynaud
Erik Wallstroem
Eric Legangneux
Philippe Michael Rene Bouillot
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52988364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201606519(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA201606519B publication Critical patent/ZA201606519B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA2016/06519A 2014-04-10 2016-09-21 S1p modulator immediate release dosage regimen ZA201606519B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461977816P 2014-04-10 2014-04-10
PCT/IB2015/052550 WO2015155709A1 (en) 2014-04-10 2015-04-08 S1p modulator immediate release dosage regimen

Publications (1)

Publication Number Publication Date
ZA201606519B true ZA201606519B (en) 2017-11-29

Family

ID=52988364

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2016/06519A ZA201606519B (en) 2014-04-10 2016-09-21 S1p modulator immediate release dosage regimen

Country Status (16)

Country Link
US (4) US20170027907A1 (enExample)
EP (3) EP3129020A1 (enExample)
JP (1) JP6674903B2 (enExample)
KR (2) KR20220156981A (enExample)
CN (2) CN106456552A (enExample)
AU (2) AU2015246036A1 (enExample)
CA (1) CA2943598C (enExample)
CL (1) CL2016002562A1 (enExample)
IL (2) IL305337A (enExample)
MX (1) MX2016013245A (enExample)
PH (1) PH12016501965A1 (enExample)
RU (2) RU2715734C2 (enExample)
SG (1) SG11201607894RA (enExample)
TW (1) TW201622721A (enExample)
WO (1) WO2015155709A1 (enExample)
ZA (1) ZA201606519B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (enExample) 2014-01-24 2018-02-24
EP3129020A1 (en) * 2014-04-10 2017-02-15 Novartis AG S1p modulator immediate release dosage regimen
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
EP3687531A1 (en) * 2017-09-29 2020-08-05 Novartis AG Dosing regimen of siponimod
CA3073910A1 (en) * 2017-09-29 2019-04-04 Novartis Ag Dosing regimen of siponimod
HUE070049T2 (hu) * 2018-03-01 2025-05-28 Astrazeneca Ab (2S)-{(1S)-1-ciano-2-[4-(3-metil-2-oxo-2,3-dihidro-1,3-benzoxazol-5-il)fenil]etil} -1,4-oxazepán-2-karboxamidot tartalmazó gyógyászati készítmények
WO2020018547A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
CN109908095A (zh) * 2019-04-08 2019-06-21 肇庆学院 一种西尼莫德片剂及制备方法
JP7749552B2 (ja) 2019-10-31 2025-10-06 イドルシア・ファーマシューティカルズ・リミテッド Ｃｘｃｒ７アンタゴニストのｓ１ｐ１受容体調節剤との合剤
US11135197B2 (en) 2020-02-07 2021-10-05 Argentum Pharmaceuticals Llc Dosage regimen of an S1P receptor modulator
JP2026503035A (ja) 2023-01-06 2026-01-27 インスメッド インコーポレイテッド 新規な可逆性ｄｐｐ１阻害剤及びその用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120115840A1 (en) * 2008-12-18 2012-05-10 Lech Ciszewski Hemifumarate salt of 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acid
JP5657565B2 (ja) 2008-12-22 2015-01-21 ノバルティス アーゲー Ｓ１ｐ受容体アゴニストの投与レジメン
TW201028143A (en) * 2008-12-22 2010-08-01 Novartis Ag Dosage regimen for a S1P receptor agonist
NZ598534A (en) * 2009-09-29 2014-03-28 Novartis Ag Dosage regimen of an s1p receptor modulator
JP6111202B2 (ja) * 2011-01-07 2017-04-05 ノバルティス アーゲー 免疫抑制製剤
WO2012095853A1 (en) 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
BR112014009141A8 (pt) * 2011-10-21 2017-06-20 Novartis Ag regime de dosagem para um modulador ou agonista do receptor s1p
EP3129020A1 (en) * 2014-04-10 2017-02-15 Novartis AG S1p modulator immediate release dosage regimen

Also Published As

Publication number Publication date
SG11201607894RA (en) 2016-10-28
RU2016143979A3 (enExample) 2018-11-12
KR20160141841A (ko) 2016-12-09
AU2020203107A1 (en) 2020-05-28
RU2715734C2 (ru) 2020-03-03
US20190054065A1 (en) 2019-02-21
EP4074312B1 (en) 2026-02-25
PH12016501965A1 (en) 2017-01-09
IL305337A (en) 2023-10-01
EP4074312A1 (en) 2022-10-19
EP4074312C0 (en) 2026-02-25
RU2016143979A (ru) 2018-05-14
CA2943598C (en) 2023-03-07
AU2015246036A1 (en) 2016-10-13
CN116650467A (zh) 2023-08-29
AU2020203107B2 (en) 2021-10-21
MX2016013245A (es) 2017-01-16
TW201622721A (zh) 2016-07-01
CA2943598A1 (en) 2015-10-15
JP6674903B2 (ja) 2020-04-01
US20170027907A1 (en) 2017-02-02
EP3831378A1 (en) 2021-06-09
IL247986A0 (en) 2016-11-30
EP3129020A1 (en) 2017-02-15
US20220016076A1 (en) 2022-01-20
US20250041266A1 (en) 2025-02-06
WO2015155709A1 (en) 2015-10-15
JP2017510607A (ja) 2017-04-13
RU2020107732A (ru) 2020-03-30
CL2016002562A1 (es) 2017-07-28
CN106456552A (zh) 2017-02-22
KR20220156981A (ko) 2022-11-28

Similar Documents

Publication Publication Date Title
IL270954A (en) Pharmaceutical compounds
IL247986A0 (en) A therapeutic regimen containing an immediate release dose of an s1p modulator
GB201404922D0 (en) Pharmaceutical compounds
PT3145836T (pt) Cápsula de dispensação
SI3022458T1 (sl) Povezava zavornega diska in pesta
PL3363428T3 (pl) Perfuzyjna postać dawkowania
IL247084A0 (en) dose fgh–18
GB201412955D0 (en) Supramolecular capsules
GB201416513D0 (en) Pharmaceutical compounds
GB201417707D0 (en) Pharmaceutical compounds
SI3145497T1 (sl) Obložene kapsule s prirejenim sproščanjem
SI3145499T1 (sl) Obložene kapsule s prirejenim sproščanjem
EP3011948A4 (en) DEVICE FOR DISPENSING RADIOPHARMACEUTICAL PRODUCTS
GB201418710D0 (en) Dosage regimen
GB2531773B (en) Medicine pack
LT3139932T (lt) Gydymo režimas su tiakumicino junginiu
HK1227759A1 (en) S1p modulator immediate release dosage regimen
GB201418708D0 (en) Dosage regimen
GB201400171D0 (en) Dosage regimen
GB201521216D0 (en) Dosage regimen
GB201508022D0 (en) Pharmaceutical compounds
AU362816S (en) Capsule
GB201416968D0 (en) Pharmaceutical compounds
GB201416969D0 (en) Pharmaceutical compounds
GB201416627D0 (en) Pharmaceutical compounds